Gene expression profiling combined with functional analysis identify integrin beta1 (ITGB1) as a potential prognosis biomarker in triple negative breast cancer

2016 ◽  
Vol 104 ◽  
pp. 31-37 ◽  
Author(s):  
Sukhontip Klahan ◽  
Wan-Chen Huang ◽  
Che-Mai Chang ◽  
Henry Sung-Ching Wong ◽  
Chi-Cheng Huang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Expression ◽  
Functional Analysis ◽  
Gene Expression Profiling ◽  
Triple Negative Breast Cancer ◽  
Expression Profiling ◽  
Triple Negative ◽  
Integrin Beta1

scholarly journals Are There Any Clinically Relevant Subgroups of Triple-Negative Breast Cancer in 2018?

2018 ◽  
Vol 14 (5) ◽  
pp. 281-289 ◽  
Author(s):  
Jack J. Chan ◽  
Tira J.Y. Tan ◽  
Rebecca A. Dent
Keyword(s):  
Breast Cancer ◽  
Gene Expression ◽  
Triple Negative Breast Cancer ◽  
Expression Profiling ◽  
Triple Negative ◽  
Treatment Strategies ◽  
Molecular Targets ◽  
Therapeutic Decisions ◽  
Definition Of ◽  
Limited Usefulness

The working immunohistochemical definition of triple-negative breast cancer (TNBC) is admittedly reductionist and has only limited usefulness for informing oncologists about therapeutic decisions beyond chemotherapy. Early molecular taxonomies of TNBC based heavily on gene expression profiling, which is not readily available in the clinic today, do not necessarily encompass other molecular targets already incorporated into rationally designed clinical trials. We state that it is possible to delineate five subgroups of TNBC relevant to present-day clinical practice and cover the evidence that lends credence to emerging biomarker-directed treatment strategies for each subgroup.

Sign in / Sign up

Export Citation Format

Share Document